Market research
ITRM Iterum Therapeutics PLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 3.01
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IE000TTOOBX0
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 3.01
About
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ITRM discussion.
5 years, 4 months ago
Iterum Therapeutics plc is currently in a long term uptrend where the price is trading 0.6% above its 200 day moving average.
From a valuation standpoint, the stock is 0.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1349.8.
Iterum Therapeutics plc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 52.7% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 54.9% to $-9M since the same quarter in the previous year.
Based on the above factors, Iterum Therapeutics plc gets an overall score of 3/5.